These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

687 related items for PubMed ID: 23760587

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
    Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, Hohenberger P.
    Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
    [Abstract] [Full Text] [Related]

  • 3. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.
    Digestion; 2013 Jan; 87(1):47-52. PubMed ID: 23343969
    [Abstract] [Full Text] [Related]

  • 7. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.
    An HJ, Ryu MH, Ryoo BY, Sohn BS, Kim KH, Oh ST, Yu CS, Yook JH, Kim BS, Kang YK.
    Ann Surg Oncol; 2013 Dec; 20(13):4212-8. PubMed ID: 24052319
    [Abstract] [Full Text] [Related]

  • 8. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, Bonenkamp JJ, van der Graaf WT, de Wilt JH.
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [Abstract] [Full Text] [Related]

  • 9. Surgical management of rectal gastrointestinal stromal tumors.
    Tielen R, Verhoef C, van Coevorden F, Reyners AK, van der Graaf WT, Bonenkamp JJ, van Etten B, de Wilt JH.
    J Surg Oncol; 2013 Mar; 107(4):320-3. PubMed ID: 22806955
    [Abstract] [Full Text] [Related]

  • 10. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.
    Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
    Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A.
    Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
    [Abstract] [Full Text] [Related]

  • 12. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
    Li SX, Li ZY, Zhang LH, Bu ZD, Wu AW, Wu XJ, Zong XL, Shan F, Ji X, Ji JF.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340
    [Abstract] [Full Text] [Related]

  • 13. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.
    Machlenkin S, Pinsk I, Tulchinsky H, Ziv Y, Sayfan J, Duek D, Rabau M, Walfisch S.
    Colorectal Dis; 2011 Oct; 13(10):1110-5. PubMed ID: 21040362
    [Abstract] [Full Text] [Related]

  • 14. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY.
    Chin Med J (Engl); 2010 Jan 20; 123(2):131-6. PubMed ID: 20137358
    [Abstract] [Full Text] [Related]

  • 15. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
    Rutkowski P, Wozniak A, Dębiec-Rychter M, Kąkol M, Dziewirski W, Zdzienicki M, Ptaszynski K, Jurkowska M, Limon J, Siedlecki JA.
    Cancer; 2011 Nov 01; 117(21):4916-24. PubMed ID: 21456019
    [Abstract] [Full Text] [Related]

  • 16. [Prognosis analysis of 216 cases of gastrointestinal stromal tumor].
    Liu LC, Xu WT.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar 01; 15(3):255-8. PubMed ID: 22454172
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
    Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL.
    Ann Surg Oncol; 2012 Apr 01; 19(4):1074-80. PubMed ID: 22203182
    [Abstract] [Full Text] [Related]

  • 18. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W.
    Med Sci Monit; 2007 Nov 01; 13(11):CR515-522. PubMed ID: 17968300
    [Abstract] [Full Text] [Related]

  • 19. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
    Ogata K, Mochiki E, Ojima H, Haga N, Fukuchi M, Aihara R, Ando H, Uchida N, Toyomasu Y, Suzuki M, Kimura A, Kogure N, Yokobori T, Ohno T, Kuwano H.
    J Surg Oncol; 2014 Dec 01; 110(8):942-6. PubMed ID: 25164620
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors.
    Seshadri RA, Rajendranath R.
    J Cancer Res Ther; 2009 Dec 01; 5(4):267-71. PubMed ID: 20160360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.